Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
83 Results for "
benign
" in MedChemExpress (MCE) Product Catalog:
Products (83)
83 Results for "benign" in MCE Product Catalog:
Cat. No.: HY-103202A
CAS No.: 157066-76-7
Target:
Research Areas:
SNAP5089 is a selective α1A-adrenoceptor antagonist with over 1700-fold selectivity for the α1A subtype, which may have implications for the treatment of hypertension and benign prostatic hypertrophy. SNAP5089 demonstrates significant receptor affinity compared to other clinical drugs, emphasizing its potential therapeutic advantages. SNAP5089's high affinity aligns with its suitability for conditions where precise α1A modulation is desirable.
Cat. No.: HY-W357141
CAS No.: 10019-60-0
Synonyms: Methyl salicylate 2-O-β-D-glucopyranoside
Target:
Cat. No.: HY-N13195
CAS No.: 420781-85-7
Category:
Target:
Cat. No.: HY-N18683
CAS No.: 84604-15-9
Cat. No.: HY-W102330
CAS No.: 90356-78-8
Target:
Research Areas:
Bicalutamide sulfide (compound 39) is a nonsteroidal antiandrogen. Bicalutamide sulfide can be used for the study of androgen-responsive benign and malignant disease .
Cat. No.: HY-183179
CAS No.: 359722-12-6
Target:
Research Areas:
α1A Adrenoceptor antagonist-1 is a selective α1A adrenoceptor antagonist with a human Ki <20 nM. α1A Adrenoceptor antagonist-1 exhibits activity against benign prostatic hyperplasia (BPH) to enable less hindered urine flow. α1A Adrenoceptor antagonist-1 relaxes α1a receptor-enriched urethral smooth muscle tissue without inducing hypotension. α1A Adrenoceptor antagonist-1 can be used for the research of benign prostatic hyperplasia (BPH) .
Target:
Research Areas:
Medrogestone is an orally active Progestin. Medrogestone shows a marked local progestational effect. Medrogestone maintains pregnancy in ovariectomized rats. Medrogestone inhibits ovulation. Medrogestone prevents pregnancy. Medrogestone produces a significant reduction in the severity of benign prostatic hypertrophy .
Cat. No.: HY-182435
CAS No.: 2803111-66-0
Target:
Research Areas:
CLE-030 is a KCNQ2 agonist with non-gating-dependent current-modulating activity . CLE-030 modulates neuronal network activity. CLE-030 can be used in studies related to pain, epilepsy and benign familial neonatal convulsions .
Cat. No.: HY-182264
CAS No.: 180634-64-4
Synonyms: Nordihydroguaiaretic acid tetrapivalate
Target:
Research Areas:
Masoprocol tetrapivalate (Nordihydroguaiaretic acid tetrapivalate) is a catecholic butane metabolite and also a tyrosine kinase activity inhibitor of IGF-1R and EGFR. Masoprocol tetrapivalate regulates tyrosine kinase signaling pathways associated with cell proliferation. Masoprocol tetrapivalate can be used in the research of proliferative diseases, including malignant, precancerous or benign cancers, and solid tumors .
Cat. No.: HY-P992475
Research Areas:
Cat. No.: HY-106391
CAS No.: 33765-68-3
Synonyms: TSAA-291
Target:
Research Areas:
Oxendolone (TSAA-291) is a steroidal antiandrogen with partial agonist properties, exhibiting a Ki value of 1.4 nM for the androgen receptor. Oxendolone exerts tissue-specific androgen receptor activity, induces unique androgen receptor conformational changes, and drives differential cofactor recruitment. Oxendolone is recruited to the androgen receptor in a PIAS1-dependent manner. Oxendolone increases levator ani muscle weight in castrated mice. Oxendolone can be used for research on benign prostatic hyperplasia .
Cat. No.: HY-103204R
CAS No.: 1215654-26-4
Research Areas:
RS100329 hydrochloride (Standard) is the analytical standard of RS100329 hydrochloride (HY-103204). This product is intended for research and analytical applications. RS100329 hydrochloride is a potent and selective α1A-adrenoceptor antagonist with pKi values of 9.6, 7.9 and 7.5 for α1A, α1D, and α1B, respectively. RS100329 hydrochloride inhibits reflex urethral contractions. RS100329 hydrochloride can be used in research of benign prostatic hyperplasia .
Cat. No.: HY-19279A
CAS No.: 171277-06-8
Target:
Research Areas:
JTH-601 Free base is a novel alpha1-adrenoceptor antagonist that exhibits potent activity in inhibiting phenylephrine-induced contractions in lower urinary tract tissues. JTH-601 Free base competitively antagonizes alpha1-adrenoceptor-mediated contractile responses, demonstrating greater potency than prazosin or tamsulosin. JTH-601 Free base is anticipated to be effective in treating urinary outlet obstruction associated with benign prostatic hyperplasia.
Cat. No.: HY-D3188
CAS No.: 2730023-28-4
Cat. No.: HY-180815
CAS No.: 1049442-53-6
Target:
Research Areas:
α1A/1D-Adrenoceptor antagonist-1 (Compound 15) is a selective α1A/1D-adrenoceptor dual antagonist with IC50 values of 20.26 and 164.9 nM. α1A/1D-Adrenoceptor antagonist-1 shows an IC50 of 1912 nM for α1B-adrenoceptor.α1A/1D-Adrenoceptor antagonist-1 can be used for research of benign prostatic hyperplasia .
Cat. No.: HY-P86917
Synonyms: AV026640 antibody; BCH antibody; benign chorea antibody; BHC antibody; Homeobox protein NK 2 homolog A antibody; Homeobox protein NK-2 homolog A antibody; Homeobox protein Nkx 2.1 antibody; Homeobox protein Nkx-2.1 antibody; Homeobox protein Nkx2.1 antibody; NK 2 antibody; AV026640 antibody; BCH antibody; benign chorea antibody; BHC antibody; Homeobox protein NK 2 homolog A antibody; Homeobox protein NK-2 homolog A antibody; Homeobox protein Nkx 2.1 antibody; Homeobox protein Nkx-2.1 antibody; Thyroid transcription factor 1 antibody; Tin man antibody; Tinman antibody; TITF 1 antibody; TITF1 antibody; TTF 1 antibody; TTF-1 antibody; TTF1 antibody
Cat. No.: HY-W011258BS
Synonyms: L-Tyrosyl-L-phenylalanine-13C9,15N TFA
Research Areas:
H-Tyr-Phe-OH- 13C9, 15N ( (L-Tyrosyl-L-phenylalanine- 13C9, 15N)) TFA is the 13C- and 15N-labeled H-Tyr-Phe-OH (HY-W011258). H-Tyr-Phe-OH (L-Tyrosyl-L-phenylalanine) is an orally active inhibitor of Angiotensin converting enzyme (ACE), with an inhibiton rate of 48% at 50 μM. H-Tyr-Phe-OH can be used as an biomarker for differentiating benign thyroid nodules (BTN) from thyroid cancer (TC). H-Tyr-Phe-OH exhibits xanthine oxidase inhibition (uric acid lowering) activity and serves as regulator in IL-8 production in neutrophil-like cells.
Cat. No.: HY-138032
CAS No.: 326914-17-4
Synonyms: N,N-Dimethyl sunitinib
Research Areas:
SU11657 (N,N-Dimethyl sunitinib) is an orally active multi-targeted tyrosine kinase inhibitor with IC50 values of 0.04 μM (c-Kit), 0.005 μM (PDGFR), 0.013 μM (VEGFR1), 0.017 μM (VEGFR2) and 50 nM (FLT3), respectively. SU11657 exhibits anti-angiogenic activity. SU11657 delays leukemia progression, synergizes with ATRA (HY-14649) to reduce leukemia burden, and inhibits symptoms and tissue damage associated with rheumatoid arthritis. SU11657 can be used in research related to FLT3-mutated acute promyelocytic leukemia, rheumatoid arthritis, neuroblastoma, and benign/atypical meningioma .
Cat. No.: HY-181774
CAS No.: 1807631-43-1
Target:
Research Areas:
PDE4/5-IN-1 is a selective phosphodiesterase 4/5 (PDE4/5) dual inhibitor. PDE4/5-IN-1 functionally inhibits PDE5, PDE4B2, and PDE4D2 activity. PDE4/5-IN-1 relaxes isolated rat prostate tissue, enhances nitric oxide-induced relaxation in isolated rat prostate tissue, and reduces alpha-1 adrenoceptor-mediated contractile responses in isolated rat prostate tissue. PDE4/5-IN-1 inhibits proliferation of human hyperplastic prostate cells. PDE4/5-IN-1 can be used for the research of benign prostatic hyperplasia .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
